Related StoriesOptimised ChIP protocols for qPCR and sequencingEfficient respiratory diagnosis solutionHighly effective ChIP assay package for FFPE samples’We are very very happy to announce this strategic collaboration with LabCorp due to the value it creates for our customers’, said Clearstone CEO Lewis Cameron. ‘LabCorp is well established in the diagnostic and clinical trials markets. This global collaboration provides LabCorp with an extended international existence to serve the global scientific trials market.Beneath the agreement, Anadis has licensed from ImmuCell a portfolio of released patents, IND filings, clinical data, manufacturing plans and know-how related to several human heath products. In particular the deal will enhance product development work for Clostridium difficile straight, E.coli and immune deficiency related opportunistic attacks. The licensed systems are related to using hyperimmune bovine colostrum to provide immediate-performing passive immunity against infectious illnesses.